论文部分内容阅读
~(123)I放射性核素在临床中的用量占加速器生产放射性同位素的13%,排名第3,仅位于~(18)F(45%)和~(201)Tl(27%)之后。目前,用于研究和应用的~(123)I标记的放射性药物主要有神经系统
The amount of ~ (123) I radionuclides used in the clinic accounted for 13% of the radioisotopes produced by the accelerator and ranked No. 3 only after ~ (18) F (45%) and ~ (201) Tl (27%). At present, the (123) I-labeled radiopharmaceutical used for research and application mainly includes the nervous system